Statins can slash arthritis risk

Image
Press Trust of India London
Last Updated : May 28 2013 | 4:31 PM IST
A daily dose of popular
cholesterol-lowering drugs called statins can more than halve the risk of developing arthritis, a new study has claimed.
Keele University studied more than 16,000 adults and found that people on the highest doses of statins - 18.5mg or more a day - had 60 per cent lower osteoarthritis rates than people not taking the drugs.
They found that taking between 10mg to 18.5mg dose of the drug a day resulted in a 20 per cent reduction in the chances of developing the disease, the 'Daily Express' reported.
Osteoarthritis causes crippling pain - usually in the hands, spine, knees and hips - as bones rub against each other as cartilage breaks down.
Researchers at the university's Health Services Research Unit and its Arthritis Research UK Primary Care Centre also found that some people on very low doses seemed to be at higher risk of arthritis than patients not taking statins.
This suggests the condition may be more closely linked to heart disease than first thought.
"Our work has shown that the risk factors for cardiovascular disease are also associated with osteoarthritis. The co-occurrence of osteoarthritis and cardiovascular disease is common," researchers wrote in the Journal of General and Internal Medicine.
Experts said more research is needed before statins could be given to patients most at risk or in the early stages of the disease.
Scientists now suspect that inflammation plays a much bigger role in osteoarthritis than first thought.
They are investigating whether drugs used in rheumatoid arthritis, which occurs when the immune system attacks the joints, can also help in osteoarthritis.
"We welcome this study as it contributes to the idea that osteoarthritis is not simply wear and tear and that in the future drug treatments can offer hope to people with the condition," a spokeswoman for Arthritis Research UK said.
"Arthritis Research UK is also looking at ways to reduce inflammation in people with osteoarthritis and we are funding trials to investigate whether drugs used in rheumatoid arthritis are also effective for people living with osteoarthritis," she added.
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: May 28 2013 | 4:31 PM IST

Next Story